Provided by Tiger Trade Technology Pte. Ltd.

Biomea Fusion, Inc.

1.37
+0.01000.74%
Post-market: 1.370.0041+0.30%19:30 EDT
Volume:575.26K
Turnover:774.04K
Market Cap:99.05M
PE:-2.91
High:1.38
Open:1.37
Low:1.32
Close:1.36
52wk High:2.99
52wk Low:0.8719
Shares:72.30M
Float Shares:67.01M
Volume Ratio:0.86
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4711
EPS(LYR):-1.1832
ROE:-164.14%
ROA:-63.46%
PB:8.16
PE(LYR):-1.16

Loading ...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)

TIPRANKS
·
Jun 24

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)

TIPRANKS
·
Jun 12

Biomea Fusion shareholders elect two directors at annual meeting

Reuters
·
Jun 11

Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained

TIPRANKS
·
Jun 08

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study

THOMSON REUTERS
·
Jun 06

Biomea Fusion - Icovamenib Data Show Muscle Preservation and Fat Reduction in Obesity and Diabetes

THOMSON REUTERS
·
Jun 06

Biomea Fusion - Icovamenib Improves Hba1c and C-Peptide in Type 1 Diabetes With No Immune Activation

THOMSON REUTERS
·
Jun 06

Biomea Fusion: Expanded Phase I Bmf-650 Study to Evaluate a Rapid One-Step Titration, Enhanced Weight Loss Potential With Oral Glp-1 Receptor Agonist

THOMSON REUTERS
·
Jun 06

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

GlobeNewswire
·
Jun 06

Biomea Fusion management to meet with Citizens

TIPRANKS
·
Jun 05

Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Jun 03

Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial

Reuters
·
Jun 03

Biomea Fusion - Study to Evaluate Icovamenib With Semaglutide for Enhanced Weight Loss

THOMSON REUTERS
·
Jun 03

Biomea Fusion Announces Research Collaboration With University of Leicester to Evaluate Icovamenib in Combination With Semaglutide in Obesity

THOMSON REUTERS
·
Jun 03

Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA)

TIPRANKS
·
May 13

Biomea Fusion to Participate at Upcoming Investor Conferences

GlobeNewswire
·
May 13

Biomea Fusion Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate

Benzinga Earnings
·
May 12

Biomea Fusion Q1 net loss narrows as expenses fall

Reuters
·
May 12

Biomea Fusion Q1 FY26 net loss narrows to $12.4 million; cash falls to $45.1 million

Reuters
·
May 12